Remove category matts-take
article thumbnail

Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2

pharmaphorum

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. In its third-quarter update, the Danish drugmaker reported sales of Rybelsus reached DKK 7.25

article thumbnail

Express Scripts on the Road to Damascus?

Ramblings of a pharmacist

This brings me to my main point today - Pharmacy Benefit Managers are exactly what Matt Stoller describes - glorified spreadsheets that get to charge everyone fees for no reason. And PBMs are REALLY good at playing with spreadsheets to move around dollars and cents and hide that money from everyone doing business with them.